

International Consortium for Trials of Chemotherapeutic Agents in Tuberculosis (INTERTB)



Seminar to discuss strategies for improving the current treatment of tuberculosis in order to be able to meet the Millenium Development Goals for the Global Eradication of Tuberculosis.

St. George's, University of London, Thursday March 22nd, 2007

DRAFT AGENDA

First morning session: Introduction: Chair Baroness Elaine Murphy

09h00 - 09h10	Welcome and introductions	Baroness Elaine Murphy
09h10 - 09h20	Tuberculosis: the problem	Dr Katherine Floyd
09h20 - 09h30	Treating tuberculosis: Old and New drugs	Prof Denis Mitchison
09h30 - 09h45	The Challenges of Phase III Trials	Prof Andrew Nunn
09h45 – 09h55	Overview of funding Phase III trials	Dr Tom Harrison
09h55 - 10h10	Discussion	

10h10 - 10h 35 Coffee break

Second morning session: The UK effort: Chair Prof. George Griffin

10h35 – 10h45	Fluoroquinolones: the Oflotub Trial	Prof Denis Mitchison
10h45 – 11h00	Fluoroquinolones: the Remox Trial	Prof Stephen Gillespie
11h00 – 11h20	Rifamycins: The Rifaquin Trial	Dr Amina Jindani
11h20 – 11h40	Rifamycins: Trials with rifabutin	Dr Bertel Squire
11h40 - 12h00	HIV/TB Drug interactions	Dr Saye Khoo
12h00 - 12h15	The role of NGOs	Dr Phillippe Guérin
12h15 - 12h30	Discussion	

12h30 - 13h30 pm LUNCH

Afternoon session: Novel strategies: Chair Prof. Anthony Coates

13h30 - 13h40	Introductory remarks	Prof Anthony Coates
13h40 - 14h00	Modelling and novel phase II designs	Dr Geraint Davies
14h00 – 14h15	The transition to shortening treatment	Prof Denis Mitchison
14h15 – 14h30	Novel strategies for assessing rifamycin resistance and treatment response	Dr Carlton Evans
14h30 – 15h00	Discussion: What to do now and in the future	Co-Moderators Prof Denis Mitchison & Dr Tom Harrison